Stage I - III Breast Cancer-Specific Survival (BCSS) Calculator
Stage IV Metastatic Breast Cancer Overall Survival (OS) Calculator
Stage IV Metastatic Breast Cancer Overall Survival (OS) Calculator
Age at the time of stage IV diagnosis (in years)
Race / ethnicity
--Select--
White
Black
Other
Karnofsky performance status
--Select--
90-100
70-80
10-60
Metastasis-free interval
?
Time in months from diagnosis of primary localized breast cancer to the first diagnosis of distant metastatic disease.
--Select--
De novo
MFI ≤ 24 months
MFI > 24 months
Number of organs involved with metastasis
--Select--
1
2
3
≥ 4
Organs involved with metastasis
--Select--
Bone only
Non-visceral (soft tissue, lymphadenopathy, skin; can include bone)
Visceral organs (lung, liver) without CNS involvement, with or without bone or non-visceral involvement
CNS involvement with or without other organ or bone involvement
ER (Estrogen receptor status)
?
ER positive: immunohistochemistry (IHC) expression ≥ 10% through the year 2010 and ≥ 1% after year 2010 ER negative: immunohistochemistry (IHC) expression < 10% through the year 2010 and < 1% after year 2010
--Select--
Negative
Positive
Unknown
PR (Progesterone receptor status)
?
PR positive: immunohistochemistry (IHC) expression ≥ 10% through the year 2010 and ≥ 1% after year 2010 PR negative: immunohistochemistry (IHC) expression < 10% through the year 2010 and < 1% after year 2010
--Select--
Negative
Positive
Unknown
HER2 (Human epidermal growth factor receptor-2 status)
--Select--
Negative
Positive
HR/HER2 status
Frontline hormone therapy
?
Initial therapy given within 90 days of the diagnosis of metastatic breast cancer.
--Select--
No
Yes
Unknown
Frontline trastuzumab or pertuzumab
?
Initial therapy given within 90 days of the diagnosis of metastatic breast cancer.
--Select--
No
Yes
Unknown
ASCO Guideline
for ER/PR IHC Testing
ASCO Guideline
for HER2 Testing
Clear
This breast cancer survival prediction tool provides 5-year based on model derived from patients who underwent surgery as their 1st treatment from 1990 to 2016 at the University of Texas MD Anderson Cancer Center and received state-of the art treatment. The tool has been validated in an external dataset from the National Comprehensive Cancer Network (NCCN) database. The information provided here may be used as an aid in discussions between physicians and patients.
